James B. Frakes - 08 Oct 2026 Form 4 Insider Report for AETHLON MEDICAL INC (AEMD)

Reporting relationship: CFO/CEO, Director
Issuer ticker: AEMD
Reported as of: 08 Oct 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Oct 2026, 21:13:25 UTC
Prior SEC filing: 11 Feb 2022
Source filing: View source filing
Reporting owner signature: /s/ James B. Frakes

Filing notes and source

Key filing fact

James B. Frakes filed Form 4 for AETHLON MEDICAL INC (AEMD) on 13 Oct 2026.

Key facts

This page summarizes James B. Frakes's Form 4 filing for AETHLON MEDICAL INC (AEMD).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 13 Oct 2026, 21:13.

Change

Previous filing in this sequence was filed on 11 Feb 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001185553 Primary reporting owner

FRAKES JAMES B

Relationship: CFO/CEO, Director
Address: 11555 SORRENTO VALLEY ROAD, SUITE 203, SAN DIEGO
Signature: /s/ James B. Frakes
Signature date: 13 Oct 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AEMD transaction

Common Stock

Award

Transaction value
Shares: +42,000
Change %: +66667%
Price: $0.000000^*
Shares after: 42,063
Date: 08 Oct 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents a grant of 42,000 restricted stock units ("RSUs") pursuant to the Issuer's 2020 Equity Incentive Plan, as amended. Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement. The RSUs vest over the one-year period following October 8, 2026, subject to the Reporting Person's continued service through the applicable vesting dates. Notwithstanding the foregoing, the RSUs will become fully vested upon the closing of the Issuer's proposed merger with North Immunology, Inc.